Fund moves
4.3%Stake · was 6.3%
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CAH · NYSE · Health Care Distributors
Cardinal Health (CAH) · oqro.io/stocks/CAH · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$272.81+0.47 (+0.17%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Cardinal Health was filed in the last 90 days. The latest on record was on Nov 15, 2022.
Since 2001, Cardinal Health insiders reported 40 open-market purchases and 290 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2022.
No open-market sale by an insider of Cardinal Health (CAH) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 1 trade in Cardinal Health (CAH) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Sen. Alan Armstrong.
Cardinal Health's next results are expected on Feb 3, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+31.2% (+$64.91) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $207.90 on Nov 20, 2025 to $272.81 on Nov 20, 2026 (+31.2%). Disclosed in this range: 35 insider trades, 0 pre-arranged insider sales, 1 Congress trade, and 70 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Distributors company based in Dublin, Ohio.
Last 12 months
+31.2%
Market value
$63.1B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.58M shares sold short (3.3% of shares outstanding), −1.3% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$254B
+14.2% vs the year before
Net income, fiscal 2026
$1.71B
As reported in the annual filing
Shares outstanding
231M
As of Oct 31, 2026
In fiscal 2026 the company spent $1.36B buying back its own shares and $491M on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Federal contracts
Radiopharmaceuticals
The Department of Veterans Affairs has committed $3.11M to Cardinal Health so far. It runs until Sep 30, 2027.
Federal contracts
Radioharm order
The Department of Veterans Affairs has committed $1.97M to Cardinal Health so far. It runs until Sep 30, 2027.
Insider selling
Traded Aug 19 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +16.2% · S&P 500 −10.3% · to Nov 20
Cardinal Health's Chief Accounting Officer sold $523K of Cardinal Health shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$67.5B
+5.5% vs the same quarter a year earlier
Free cash flow, last 12 months
$4.9B
This quarter $1.24B, a year earlier $865M
Net debt
$1.67B
Debt $6.93B, cash $5.26B, at Sep 30, 2026
Net income, last 12 months
$1.82B
Operating profit covers interest 7.51x (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 19 fiscal yearsRevenue breakdown: where the money goesCompared with its peersEarnings dates and the stock's moves
On the public record for Cardinal Health over the 12 months to Nov 22, 2026: 42 FDA records (9th most among listed companies) and 22 executive contributions.
Against the S&P 500 over the year
Since Nov 19, 2025, CAH is up 31.5% and the index fund is up 4.1%: 27 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CAH moves
Beta 0.0 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insiders of Cardinal Health reported 40 open-market purchases and 290 sales since 2001; purchases in 8 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $61.6M35×35 trades |
| 2025 | — | $50.9M19×19 trades |
| 2024 | — | $22.1M11×11 trades |
| 2023 | — | $15.7M11×11 trades |
| 2022 | $48K4×4 trades | $6.5M2×2 trades |
| 2021 | $10K1×1 trade | $843K3×3 trades |
| 2018 | — | $4.01M7×7 trades |
| 2017 | — | $18.6M3×3 trades |
| 2016 | — | $57.3M13×13 trades |
| 2015 | $121K2×2 trades | $100M12×12 trades |
| 2014 | — | $104M32×32 trades |
| 2013 | $20K1×1 trade | $64.1M36×36 trades |
| 2012 | — | $8.43M8×8 trades |
| 2011 | — | $14.2M21×21 trades |
| 2010 | — | $24K1×1 trade |
| 2009 | — | $714K3×3 trades |
| 2007 | $1.15M26×26 trades | $10.3M53×53 trades |
| 2006 | — | $16.4M20×20 trades |
| 2003 | $4331×1 trade | — |
| 2002 | $1.6K4×4 trades | — |
| 2001 | $3701×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Vanguard Capital Management
13G · passive · Crossed 5% · 17.6M shares · filed Apr 29, 2026
Vanguard Portfolio Management
13G · passive · Crossed 5% · 13.8M shares · filed Apr 29, 2026
Recent moves
Wellington Management Group LLP fell below 5% (4.3%) · Schedule 13G, 2026
Wellington Management Group LLP went above 5%, with 6.3% · Schedule 13G, 2026
Vanguard Capital Management went above 5%, with 7.49% · Schedule 13G, 2026
Vanguard Portfolio Management went above 5%, with 5.85% · Schedule 13G, 2026
The Vanguard Group fell below 5% (0%) · Schedule 13G, 2026
BlackRock Portfolio Management LLC fell below 5% (3.8%) · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by software from the filings listed below · Nov 21, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records
Latest annual report filed Aug 11, 2026, compared with the one filed Aug 12, 2025. Read the filing
Source: SEC EDGAR, Form 10-K filed Aug 11, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
People read Cardinal Health's Wikipedia article about 100 times a day over the last week, close to the 120 on a usual day of the three months before.
May 16, 2026Busiest day: 230 views on Jun 2, 2026Nov 21, 2026
Views of the article Cardinal Health, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 3, 2027
Purchases after results
Not enough history
From Cardinal Health's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Cardinal Health's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
1 approval or clearance and 41 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
46 certified in FY2026 Q3, vs 28 a year earlier. 46 positions in total, median offered wage $111K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
+5.7% on the same quarter a year earlier ($59.2B). Operating income $783M, a 1% margin
+0.2% on the same quarter a year earlier ($3.18B). Operating income $33M, a 1% margin
+7.5% on the same quarter a year earlier ($1.64B). Operating income $193M, a 11% margin
+5.5% on the same quarter a year earlier ($63.6B)
+1.0% on the same quarter a year earlier ($419M)
Fiscal year Jul 1, 2025 to Jun 30, 2026, from the annual report filed Aug 11, 2026. Read the filing
+15% on the year before ($205B). Operating income $2.78B, a 1% margin
+0.7% on the year before ($12.6B). Operating income $258M, a 2% margin
+26% on the year before ($5.38B). Operating income $707M, a 10% margin
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 11,000 words.
Revenue for fiscal 2026 increased 14 percent to $254.2 billion from the prior year, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Aug 11, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
+14% on the year before ($221B)
+2.2% on the year before ($1.67B)
Short sale volume: 64.1% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 47.3%. FINRA daily files, to Nov 20, 2026.
Fails to deliver: 4,503 shares (about $1.08M) were not delivered on time for settlement on Oct 9, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 47.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.8% on ATS, 20.3% with other brokers), above its 26-week average of 43.9%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (12.3%), INTELLIGENT CROSS LLC (11.4%), SIGMA X2 (10.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.